University of Toledo U.S. Patents

This collection includes United States patents for inventions by UT faculty, students and staff that list UT/MCO/MUO as the original assignee (owner). These patents include those assigned to the University of Toledo as well as to the Medical College of Ohio/Medical University of Ohio prior to the merger in 2006. Only granted patents, not patent applications, are included. Use the 'Search within this Series' box to search for keywords in the authors, titles, or abstracts of the patents.

The University of Toledo, Technology Transfer Website

Pages

Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
Modified plasminogen activator inhibitor type-1 and methods based thereon
The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modifide PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome.
Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction
A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
IL-12 enhancement of immune responses to T-independent antigens
The present invention relates to a method of modulating an immune response to a T-cell or thymus independent antigen in a host (e.g., mammalian, including human), comprising administering to the host an effective amount of interleukin-12 (IL-12) and the T-cell independent antigen. In one embodiment, the present invention relates to a method of inducing an immune response to a TI antigen in a host (e.g., mammalian, including human), which comprises administering to the host an effective amount of interleukin-12 (IL-12) and the TI antigen. In another embodiment, the present invention relates to a method of enhancing an immune response against a TI antigen in a host, which comprises administering to the host an effective amount of IL-12 and the TI antigen. The methods of the present invention can be used, for example, to induce and or enhance a humoral immune response (IgG2a and/or IgG3 humoral immune response).
Materials and methods for isolating IgA immunoglobulins
The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
IL-12 Stimulation of Neonatal immunity
The present invention relates to a method of inducing a Th1-like response against a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen. Also encompassed by the present invention is a method of overcoming suppression of interferon-? (IFN-?) expression in a neonatal host due to exposure of the neonatal host to a pathogen or an antigen, which comprises administering to the neonatal host an effective amount of IL-12 and the antigen. The present invention also relates to a method of enhancing the cytokine expression against or in response to a pathogen in a neonatal host, which comprises administering to the neonatal host an effective amount of IL-12 and an antigen of the pathogen.
Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
A method and apparatus for quantitative measurement of gene expression through multiplex competitive reverse transcriptase polymerase chain reaction amplification are disclosed. The method and apparatus are especially useful for analysis of small specimens of cells and tissues.
Method for treating bioorganic and wastewater sludges
The method of treating wastewater or bioorganic sludges containing odor, animal viruses, pathogenic bacteria, and parasites to produce a bioactive but stabilized product that is useful as a soil substitute or as a fertilizer which can be applied directly to lands which consists essentially of the following steps: mixing said sludge with at least one alkaline material, wherein the amount of added material mixed with said sludge is sufficient to raise the pH of said mixture to pH 12, and raise the conductivity to disinfect and stabilize the sludge, and adding green waste at different process locations so that a biological action occurs converting the greenwaste into a soil-like granular product with improved odor over that of the treated municipal sludge alone or a composted greenwaste alone.
Stable cell lines capable of expressing the adeno-associated virus replication gene
Stable packaging cell lines derived from human 293 cells which are transfected with an AAV vector having the AAV rep gene operably line to a heterologous transcription promoter, such as the metallothionein promoter, or an AAV Rep78 insensitive homologous promoter and which are capable of producing AAV Rep proteins and being useful for packaging recombinant AAV vectors containing target polynucleotides.
Gene and method for production of an IgA binding protein
The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG. The invention also pertains to methods for detecting IgA.
Gene and method for production of an IgA binding protein
The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
Use of photodynamic therapy to treat prostatic tissue
The present invention provides a method for diagnosing or treating prostatic tissue in a human or animal patient which comprises sensitizing the prostatic tissue with an effective amount of a photosensitive composition which accumulates in the prostatic tissue and exposing the sensitized tissue to a source of light energy for a predetermined time and intensity sufficient to cause cellular and/or tissue function of the sensitized prostatic tissue to diminish or cease.
Biologically relevant methods for the rapid determination of sterility
The invention is directed to biological processes and apparatus for determining the efficacy of a sterilization cycle based upon the recovery of activity of interactive enzyme systems comprising enzymes, coenzymes, catalysts, cofactors, substrates or any other necessary reagents. The invention provides a vital process for expediting sterility verification before utilization of the articles thought to be sterilized. The invention involves the rapid detection of any surviving interactive enzymatic activity which directly relates to the probability of any biological spores surviving in a test sample. An absence of a change indicates that the sterilization process had inactivated the enzyme system thereby preventing the interactive reaction from taking place which is a rapid equivalent to directly detecting the survivability of bacterial spores in a similar test. The methods and apparatus of the invention are useful in the health care industry such as in hospitals, laboratories, and research institutions, in food and environmental technology, and in all technologies which utilize sterilization in manufacturing, production or waste disposal.
Gene and method for production of a 40-45-kDa IgA binding protein
The subject invention concerns novel polynucleotide sequences which code for polypeptides which bind IgA. A further aspect of the invention are hybrid proteins (and genes encoding these hybrid proteins) which comprise binding domains for both IgA and IgG.
Photochemical ablation of gastro-intestinal tissue for augmentation of an organ
The present invention provides a method for treating a human or animal patient amenable an organ augmentation with gastro-intestinal tissue which is, or will be surgically transplanted into the patient's organ. The gastro-intestinal tissue is sensitized with an effective amount of a photosensitive composition which accumulates in the gastro-intestinal tissue. The sensitized tissue is exposed to a source of electromagnetic radiation energy for a predetermined time, wavelength and intensity sufficient to cause cellular and/or mucosal tissue function of the sensitized tissue to diminish or cease.
Exercise device
An exercise device for the lower extremities that can be mounted on a support and has a frame having a first leg and a second leg. The first and second legs have a first end and a second end. The first end of the first and second legs are pivotally connected. A cylinder is connected to the first and second legs for providing resistance. The resistance is produced when the second end of the second leg is moved in a direction toward the first leg. A resilient spring is connected to the second leg. The resilient spring moves the second end of the second leg away from the first leg. A control valve is operatively connected to the cylinder for varying the resistance of the cylinder. A pad is positioned on the second end of the first leg. The pad is positioned to be engaged by the user to pivot the second end of the first leg towards said second leg against the resistance provided by the cylinder. The resilient spring moves the second end of the first leg away from the second leg to return the first leg to the original position. The user repetitively moves the second end of the first leg towards the second leg to exercise the lower extremity.
Mechanical assist device for inserting catheters
The application discloses a mechanical assist device for the insertion of a catheter unit into the vein of a patient. The device includes a needle unit, a catheter unit, and a handle member having at least one strut member which engages the catheter unit. The strut member is manually displaced such that the catheter unit is slideably displaced over the needle unit.
(4-L-Threonine)-Mesotocin
A novel biologically active (4-L-threonine)-mesotocin which is an analog of mesotocin in which the glutamine residue in position four is replaced by a threonine residue.

Pages